Our study has linked elevated plasma concentrations of AP of complement activation products in AMD patients to polymorphic variations in the CFH gene which codes for the main regulator of the AP of complement activation in the fluid phase and on cell surfaces [13]. The gene discussed is CFH; the disease is age-related macular degeneration.